Clinical Trial
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study
Affiliations
- PMID: 15792214
Item in Clipboard
Clinical Trial
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study
Acta Orthop Belg.
2005 Feb.
Abstract
Eighteen osteoporotic (Z-score at or below 2.5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate. One year after treatment, bone densitometry showed an improvement in all patients: a mean increase of 13% +/- 15% standard deviation (SD) (p < 10(-5)) on the global data, and a mean increase of 27% +/- 15% (p < 10(-5)) on the most significant area for each individual patient. Clinical improvement was found in all patients, with a decrease in pain on manipulation, and no new fractures. No major adverse effects were reported. Cyclic intravenous administration of pamidronate is a useful tool in the treatment of osteoporosis in these children.
Similar articles
-
Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders.Ann Phys Rehabil Med. 2011 Sep;54(6):348-58. doi: 10.1016/j.rehab.2011.07.002. Epub 2011 Jul 28. Ann Phys Rehabil Med. 2011. PMID: 21840280 English, French.
-
Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.Dev Med Child Neurol. 2006 Sep;48(9):709-12. doi: 10.1017/S0012162206001526. Dev Med Child Neurol. 2006. PMID: 16904014 Clinical Trial.
-
Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy.Dev Med Child Neurol. 2010 Sep;52(9):837-42. doi: 10.1111/j.1469-8749.2010.03676.x. Epub 2010 Jun 22. Dev Med Child Neurol. 2010. PMID: 20573180
-
Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.Clin Ther. 2005 Apr;27(4):361-76. doi: 10.1016/j.clinthera.2005.04.005. Clin Ther. 2005. PMID: 15922811 Review.
-
[Bone diseases with Pain. Osteoporosis].Clin Calcium. 2007 Apr;17(4):606-12. Clin Calcium. 2007. PMID: 17404492 Review. Japanese.
Cited by
-
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2017 Jan 24;1(1):CD010899. doi: 10.1002/14651858.CD010899.pub2. Cochrane Database Syst Rev. 2017. PMID: 28117876 Free PMC article.
-
The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.Osteoporos Int. 2017 Feb;28(2):597-608. doi: 10.1007/s00198-016-3774-5. Epub 2016 Oct 24. Osteoporos Int. 2017. PMID: 27774565
-
Zoledronic acid in pediatric metabolic bone disorders.Transl Pediatr. 2017 Oct;6(4):256-268. doi: 10.21037/tp.2017.09.10. Transl Pediatr. 2017. PMID: 29184807 Free PMC article. Review.
-
Assessment of the Admission and Follow-up Characteristics of Children Diagnosed with Secondary Osteoporosis.J Clin Res Pediatr Endocrinol. 2024 Dec 4;16(4):466-474. doi: 10.4274/jcrpe.galenos.2024.2024-4-4. Epub 2024 Jul 2. J Clin Res Pediatr Endocrinol. 2024. PMID: 38953735 Free PMC article.
-
Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child.Osteoporos Int. 2016 Jul;27(7):2379-2382. doi: 10.1007/s00198-016-3528-4. Epub 2016 Feb 18. Osteoporos Int. 2016. PMID: 26892041